Page 2 | Certara

Announcement

Certara Appoints Dr. Britta Wagenhuber as Head of Quantitative Systems Pharmacology (QSP) Consultancy

Dr. Britta Wagenhuber has joined the company as Head of Quantitative Systems Pharmacology (QSP) Consultancy.

CertaraApril 8, 2026

Conference

AMWA NorCal Pacific Coast Conference

Danielle PillsburyApril 8, 2026

Case Study

How Certara Enabled Fruquintinib FDA Approval for Metastatic Colorectal Cancer

HUTCHMED was preparing a New Drug Application (NDA) submission for FRUZAQLA® (fruquintinib) a drug developed…

CertaraApril 7, 2026

Webinar

Earning Regulatory Trust: Practical Strategies to Increase Model Acceptance in MIDD

CertaraApril 6, 2026

Blog

CDISC SEND Updates Nonclinical Drug Developers Need to Know

In this blog, Peggy Zorn explores updates to the Standard for Exchange of Nonclinical Data…

CertaraApril 6, 2026

Webinar

Final ICH M15 Guidance: Aligning MIDD with Global Regulatory Expectations

Danielle PillsburyApril 2, 2026

Webinar

Is your compound registration system holding you back?

Danielle PillsburyApril 2, 2026

Publication

Integrated Population Pharmacokinetic, Pharmacodynamic, and Safety Analyses to Inform Dosage Selection in the Clinical Development of the ATR Inhibitor Tuvusertib

This study demonstrates how a model-informed, totality-of-evidence approach was used to select the optimal clinical…

Danielle PillsburyApril 2, 2026

Press Coverage

FDA Blueprint Aims To Cut Regulatory Risk for Alternatives to Animal Testing

The FDA’s new draft guidance clarifies how drug developers can validate and use non-animal testing…

CertaraApril 1, 2026

Infographic

6 ways Pinnacle 21 Enterprise centralized validation across studies

Learn how to centralize clinical data validation across studies using Pinnacle 21 Enterprise to improve…

CertaraApril 1, 2026

Certara Appoints Dr. Britta Wagenhuber as Head of Quantitative Systems Pharmacology (QSP) Consultancy

AMWA NorCal Pacific Coast Conference

How Certara Enabled Fruquintinib FDA Approval for Metastatic Colorectal Cancer

Earning Regulatory Trust: Practical Strategies to Increase Model Acceptance in MIDD

CDISC SEND Updates Nonclinical Drug Developers Need to Know

Final ICH M15 Guidance: Aligning MIDD with Global Regulatory Expectations

Is your compound registration system holding you back?

Integrated Population Pharmacokinetic, Pharmacodynamic, and Safety Analyses to Inform Dosage Selection in the Clinical Development of the ATR Inhibitor Tuvusertib

FDA Blueprint Aims To Cut Regulatory Risk for Alternatives to Animal Testing

6 ways Pinnacle 21 Enterprise centralized validation across studies

Newsletter sign up

Quick links

Solutions

Contact